The pharmacodynamics of i.v. and subcutaneous (s.c.) tinzaparin sodium compared with heparin in healthy volunteers were studied. A randomized, open-label, five-treatment, five-period-crossover study ...

According to a new study published in JAMA, treatment with low molecular-weight heparin tinzaparin did not significantly reduce recurrent venous thromboembolism (VTE) or major bleeding and overall ...

Prospective and working memory decline as a result of impaired sleep and/or impared blood glucose in breast cancer patients during chemotherapy treatment. Background: VTE is a major cause of morbidity ...

Hospitalization rate differences among cancer patients on biologics and biosimilars. HTB patients with active LC related to 4 factors: disease, treatment, biomarker and patient features.

The inhibitory effect of anti-thrombin III (AT-III) on thrombin, factor IIa and other coagulation serine proteases in plasma is increased several thousand-fold by Tinzaparin. This inhibition accounts ...

Please provide your email address to receive an email when new articles are posted on . Extended thromboprophylaxis with weight-adjusted tinzaparin appeared safe and effective for patients following ...

Please provide your email address to receive an email when new articles are posted on . The use of daily tinzaparin for 6 months did not significantly reduce recurrent venous thromboembolism, major ...

Tinzaparin (Innohep (10000 iu)) is an anticoagulant, prescribed for deep vein thrombosis with or without pulmonary embolism.It works by blocking the formation of blood clots. The information provided ...

Details concerning the Tinzaparin medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.

Assays were linear over the range from 0.0 to 1 IU/mL for anti-Xa activity (mean r = 0.994 [n = 114], range = 0.995-1.0) and from 0 to 0.4 IU/mL for anti-IIa activity (mean r = 0.9963 [n = 71], range ...